UQ IMB spinout company, Protagonist Therapeutics Inc., recently announced that it has initiated a Phase 1 clinical study for a potential treatment of iron overload in rare diseases, which will be the company’s second candidate into clinical development.
Read the full announcement (25 May)
Today, Protagonist Therapeutics Inc. announced it has entered into a $1 billion worldwide agreement with Janssen Biotech to co-develop and commercialise an oral peptide drug candidate for inflammatory bowel disease.
Read the full announcement (30 May)
Last year, Protagonist Therapeutics listed on the NASDAQ exchange last year, raising $118 million in its initial public offering.
The company, founded by IMB Group Leader Associate Professor Mark Smythe, is headquartered in Newark, California with its pre-clinical and clinical staff in California, and discovery operations both in California and here at UQ IMB in Brisbane, Australia.
